BRAF and colorectal carcinoma: In CHRONOS, CRC patients approaching third or later line of treatment were assessed for RAS, BRAF and EGFR ectodomain status in ctDNA and rechallenged with anti-EGFR treatment only if a mutation-negative status was found [92].